Following the Phase II faceoff between two of Scancell’s lead melanoma immunotherapy candidates, the biotech has selected ...

Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...

SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type ...

Scancell Holdings, the developer of Immunobody and Moditope active immunotherapies to treat cancer, has announced further positive data from the ongoing Phase II SCOPE trial of SCIB1/iSCIB1+ ...

Adding SCIB1 or iSCIB1+ to standard treatments helped more patients with advanced melanoma respond and live longer without ...

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site, we cannot ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Scancell Holdings Share Chat. Chat About SCLP Shares - Stock Quote, Charts, Trade History, Share Chat, Financial Terms Glossary.

Find out if Scancell Holdings PLC (SCNLF:PINX) stock is overpriced or undervalued based on Morningstar's evaluation. Assess the current comparison of market prices to the Fair Value of the company ...

Review the current Scancell Holdings PLC (SCP:XFRA) dividend yield and history to decide if SCP is the best investment for you.

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety ...